China Genomics Market (2025-2030)
The China Genomics Market was valued at $1547.1 Million in 2025 and projected to reach to $2336.3 Million by 2030, representing a compound annual growth rate of 8.6%. China's In Situ Hybridization market is poised for significant growth, supported by rising healthcare expenditure, increasing cancer incidence, and government backing for genomic technologies.
China Genomics Market Trends and Insights
- In Situ Hybridization enables precise spatial localization of nucleic acid sequences within tissue samples, making it indispensable for diagnostic and research applications across pathology and oncology.
- The In Situ Hybridization market is projected to expand to $2,336.3 million by 2030, reflecting steady adoption driven by advances in multiplexing capabilities and integration with digital pathology workflows. Growth in the In Situ Hybridization segment is underpinned by increasing demand for companion diagnostics, rising cancer prevalence, and the shift toward personalized medicine.
- In Situ Hybridization technologies, including fluorescence and chromogenic variants, are becoming standard tools in clinical laboratories and research institutions.
- The forecast period (2025–2030) will witness accelerated adoption as In Situ Hybridization platforms become more automated, cost-effective, and compatible with emerging genomic analysis frameworks..
Key Market Statistics
- CAGR (2025-2030) 8.6% CAGR
- Market Size, 2025 ~USD 1547.1 Million
- Forecast, 2030 ~USD 2336.3 Million
- Country China
China Genomics Market Overview
Rapid Market Expansion :
China's genomics market is experiencing robust growth with an 8.6% CAGR, driven by increasing investments in precision medicine and government support for biotechnology development. The market is expected to grow from $1,547.1 million in 2025 to $2,336.3 million by 2030.
Rising Oncology Demand :
In Situ Hybridization adoption in China is accelerating due to growing cancer prevalence and the need for accurate tumor diagnosis. Chinese hospitals and diagnostic centers are increasingly implementing ISH technologies for pathology applications.
Government Initiatives :
China's healthcare modernization policies and investments in genomic research infrastructure are creating favorable conditions for ISH market growth. National initiatives promoting precision diagnostics are driving technology adoption across tier-1 and tier-2 cities.
Competitive Landscape :
Local Chinese biotech companies are emerging alongside international players, creating a dynamic competitive environment. Partnerships between domestic firms and global leaders are accelerating technology transfer and market penetration in China.
China Genomics Market Dynamics
- The 8.6% CAGR reflects strong demand from diagnostic laboratories, research institutions, and hospitals seeking advanced molecular pathology solutions.
- Urbanization and improved healthcare access in secondary cities are expanding the addressable market beyond major metropolitan areas. The forecast period through 2030 will be characterized by technological advancement, increased automation, and integration with digital pathology platforms.
- Chinese manufacturers are developing cost-effective ISH solutions tailored to local market needs, while international companies are establishing regional hubs.
- Regulatory improvements and reimbursement policies will further accelerate adoption, positioning China as a key growth driver in the global genomics market..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Qiagen N.V.
- Agilent Technologies, Inc.
- Danaher Corporation
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- In Situ Hybridization market valued at $1,547.1M in 2025, expanding to $2,336.3M by 2030 at 8.6% CAGR
- In Situ Hybridization is essential for spatial genomics and companion diagnostic applications in oncology and pathology
- Multiplexing and digital integration are key drivers accelerating In Situ Hybridization adoption in clinical workflows
- In Situ Hybridization demand is fueled by personalized medicine trends and rising cancer diagnostic requirements
Genomics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.6% from 2025 to 2030 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 47.01 (2025) |
| Revenue Forecast (Billions) | ~USD 85.09 (2030) |
| Segments Covered | Offering, Type, Technology, End User, Study Type, Application |
China Genomics Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Bioinformatics Services
- Bioinformatics Tools
- Cancer Diagnostics
- Genomic Profiling & Sequencing Services
- Infectious Disease Diagnostics
- Instruments
- Other Diagnostic Applications
- Reagents, Kits, And Consumables
- Reproductive Health Diagnostics
- Sample Preparation & Library Preparation Services
By Technology
- Flow Cytometry
- Gene Editing
- In Situ Hybridization
- Microarrays
- Other Technologies
- Pcr
- Sequencing
By End User
- Academic & Research Institutes
- Cros
- Hospitals, Diagnostic Laboratories, And Clinics
- Other End Users
- Pharmaceutical & Biotechnology Companies
By Study Type
- Biomarker Discovery
- Epigenomics
- Functional Genomics
- Other Study Types
- Pathway Analysis
By Application
- Agriculture & Animal Research
- Diagnostics
- Drug Discovery & Development
- Other Applications
Target Audience
- Diagnostic Equipment Manufacturers : Need market sizing and growth forecasts to plan product development, manufacturing capacity, and market entry strategies in China's expanding genomics diagnostic sector.
- Healthcare Investment Firms : Require detailed market analysis and financial projections to evaluate investment opportunities in Chinese genomics companies, diagnostic labs, and precision medicine ventures.
- Hospital & Laboratory Administrators : Seek market intelligence to justify capital expenditures for ISH equipment, benchmark against peer institutions, and plan genomics service expansion within China's healthcare system.
- Pharmaceutical & Biotech Companies : Need China-specific market data to develop companion diagnostics strategies, identify partnership opportunities, and understand the competitive landscape for precision oncology solutions.
- Government & Policy Makers : Require market insights to inform healthcare policy, research funding decisions, and regulatory frameworks supporting genomics technology adoption and precision medicine initiatives in China.
Key Companies in the China Genomics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABCAM PLC | United Kingdom | Private Company | Reagents (antibodies, proteins, peptides, biochemicals),Kits (conjugation, cellular activity, pathway tools, immunoassays),Instruments and tools-adjacent products, |
| AFFYMETRIX INC | United States | Private Company | Reagents,Kits,Instruments, |
| BECKMAN COULTER | United States | Private Company | Instruments (flow cytometers, centrifuges, capillary electrophoresis, liquid handlers, analyzers),Reagents & Kits (sample prep, library construction, single-cell PCR, immunoassay),Genome Profiling & Genomic Services, |
| CEPHEID INC. | United States | Private Company | Instruments (GeneXpert, SmartCycler),Reagents & Kits (Xpert tests and related consumables),Services (Genome profiling, bioinformatics, support), |
| CORNING, INC. | United States | Public Company | Reagents and Kits,Instruments and Lab Equipment,Labware and Specialty Surfaces for Genomics, |
| DECODE GENETICS | Iceland | Private Company | Reagents,Kits,Instruments, |
| GENOMIC HEALTH INC | United States | Private Company | Genomic-based diagnostic services (oncology),Genome profiling services beyond core oncology,Bioinformatics and data-related services, |
| UNILABS | Switzerland | Private Company | Reagents,Kits,Instruments, |
| MAXCYTE, INC | United States | Public Company | Instruments (ExPERT ATx, STx, GTx, VLx),Consumables (Processing Assemblies, buffers, accessories),Licensing and technology access, |
| DANAHER CORPORATION | United States | Public Company | Reagents and Kits,Instruments (Sequencing-adjacent, PCR, Flow Cytometry, Sample Prep),Services (Genome Profiling, Bioinformatics, Custom Development), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Instruments (sequencing-adjacent, PCR, flow cytometry, ISH platforms),Reagents and Kits,Genomics Services (Genome Profiling, CDMO, and Lab Services), |
| REVVITY | United States | Public Company | Reagents & Kits,Instruments,Genome Profiling Services, |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | United States | Public Company | Reagents,Kits,Instruments, |
| IQVIA INC. | United States | Public Company | Genomics Services – Genome Profiling & Central Labs,Bioinformatics & Real-World Genomics Analytics,Genomics-Enabled Clinical Research Services, |
| CHARLES RIVER LABORATORIES | United States | Public Company | Reagents,Kits,Instruments, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Reagents,Kits,Instruments, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Reagents,Kits,Instruments, |
| PACBIO | United States | Public Company | Instruments (Revio, Sequel, Vega, Onso),Reagents & Kits (SMRT cells, prep, binding, sequencing kits),Services (Genome profiling, bioinformatics and related), |
| OXFORD NANOPORE TECHNOLOGIES PLC. | United Kingdom | Public Company | Instruments (MinION, GridION, PromethION family),Reagents & Kits,Genome Profiling & Sequencing Services, |
| TAKARA BIO INC. | Japan | Private Company | Reagents,Kits,Instruments, |
ABCAM PLC
Abcam PLC is a United Kingdom-based private company founded in 1998 with 1,760 employees that develops and supplies research reagents and tools for the life sciences industry.
AFFYMETRIX INC
Affymetrix Inc. is a United States-based private company founded in 1991 with 1,150 employees focused on molecular biology and genomic analysis technologies.
BECKMAN COULTER
Beckman Coulter is a United States-based private company founded in 1935 with 11,900 employees that manufactures and distributes laboratory instruments and diagnostic equipment.
CEPHEID INC.
Cepheid Inc. is a United States-based private company founded in 1996 with 1,700 employees that develops molecular diagnostic systems and point-of-care testing solutions.
CORNING, INC.
Corning, Inc. is a United States-based public company founded in 1851 with 67,200 employees that manufactures specialty glass, ceramics, and laboratory equipment.
DECODE GENETICS
deCODE Genetics is an Iceland-based private company founded in 1996 with 331 employees focused on genomic research and genetic analysis.
GENOMIC HEALTH INC
Genomic Health Inc. is a United States-based private company founded in 2000 with 829 employees specializing in genomic-based diagnostic testing.
UNILABS
Unilabs is a Switzerland-based private company founded in 1987 with 1,897 employees providing clinical laboratory and diagnostic testing services.
MAXCYTE, INC
MaxCyte, Inc. is a United States-based public company founded in 1998 with 91 employees developing cell engineering and electroporation technologies.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating a diversified portfolio of businesses including life sciences and diagnostics.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees manufacturing analytical instruments and life sciences equipment.
REVVITY
Revvity is a United States-based public company founded in 1937 with 11,000 employees providing analytical instruments and life sciences solutions.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Laboratory Corporation of America Holdings is a United States-based public company founded in 1995 with 66,385 employees operating one of the largest clinical laboratory networks.
IQVIA INC.
IQVIA Inc. is a United States-based public company with 93,000 employees providing clinical research, data analytics, and technology solutions to the pharmaceutical and healthcare industries.
CHARLES RIVER LABORATORIES
Charles River Laboratories is a United States-based public company founded in 1947 with 19,000 employees providing preclinical and clinical laboratory services for drug development.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees manufacturing and distributing life science research and clinical diagnostic products.
EUROFINS SCIENTIFIC
Eurofins Scientific is a Luxembourg-based public company founded in 1987 with 65,694 employees providing laboratory testing and analytical services across multiple industries.
PACBIO
PacBio is a United States-based public company founded in 2000 with 485 employees developing long-read DNA sequencing technologies.
OXFORD NANOPORE TECHNOLOGIES PLC.
Oxford Nanopore Technologies PLC. is a United Kingdom-based public company founded in 2005 with 1,316 employees specializing in nanopore-based DNA and RNA sequencing technologies.
TAKARA BIO INC.
Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees providing molecular biology reagents and biotechnology products.
Reasons to Buy this Report
- Localized Market Intelligence : Gain deep insights into China-specific market dynamics, regulatory environment, and competitive landscape that differ significantly from global trends. Understand local adoption patterns and barriers unique to the Chinese healthcare system.
- Growth Opportunity Identification : Identify high-potential segments and geographic regions within China experiencing accelerated ISH adoption. Discover emerging opportunities in tier-2 and tier-3 cities where market penetration is still developing.
- Strategic Partnership Guidance : Evaluate local competitors, potential partners, and distribution channels specific to China. Make informed decisions about market entry strategies, joint ventures, and collaboration opportunities with Chinese biotech firms.
- Investment Decision Support : Access comprehensive financial projections and market sizing data for China to support investment decisions, business planning, and resource allocation. Benchmark performance against regional growth rates and global comparisons.
- Regulatory & Reimbursement Insights : Understand China's evolving regulatory framework, approval processes, and reimbursement policies affecting ISH technology adoption. Navigate compliance requirements and pricing strategies tailored to the Chinese market.
Frequently asked questions
What is the market size of In Situ Hybridization in 2025?
In Situ Hybridization market is valued at $1,547.1 million in 2025.
What is the projected market size for In Situ Hybridization by 2030?
In Situ Hybridization market is forecast to reach $2,336.3 million by 2030.
What is the CAGR for In Situ Hybridization?
In Situ Hybridization is expected to grow at a compound annual growth rate of 8.6% from 2025 to 2030.
What are the primary applications of In Situ Hybridization?
In Situ Hybridization is primarily used for companion diagnostics, cancer detection, gene expression mapping, and spatial genomics research in clinical and research laboratories.
What factors are driving growth in the In Situ Hybridization market?
In Situ Hybridization growth is driven by increasing cancer prevalence, demand for personalized medicine, advances in multiplexing technology, and integration with digital pathology platforms.
RESEARCH METHODOLOGY
This research study utilized extensive secondary sources, directories, and databases to identify and collect valuable information for analyzing the global genomics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to gather and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive, technical, market-oriented, and commercial study of the genomics market. The secondary sources used for this study include Nucleic Acids Research, Genome Biology, the International Journal of Genomics, the National Human Genome Research Institute (NHGRI), the International Chromosome and Genome Society (ICGS), Genome Canada, the European Society of Human Genetics (ESHG), Genomics England, Genome British Columbia, Beijing Institute of Genomics, the Centre for Cellular & Molecular Biology (CCMB), São Paulo Research Foundation (FAPESP), Nature Reviews Genetics, Nature Methods, the Biotechnology and Biological Sciences Research Council (BBSRC), the Organisation for Economic Co-operation and Development (OECD), Genome Research, the National Cancer Institute (NCI), the European Medicines Agency (EMA), the Population Health Research Institute (PHRI), PubMed, World Bank, the World Health Organization (WHO), Eurostat, and Factiva; research journals; corporate filings, such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, and professional associations, among others. These sources were also utilized to gather key information about major players, market classification, and segmentation, as well as industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
After acquiring foundational knowledge about the global genomics market through secondary research, extensive primary research was conducted. Multiple interviews were held with market experts from the demand side, including representatives from academic & research institutes, hospitals, clinics & diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. Additionally, experts from the supply side were interviewed, including C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
These interviews spanned six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while the remaining 30% were with demand-side participants. The primary data was collected through various methods, including questionnaires, emails, online surveys, personal interviews, and telephone interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the genomics market. These methods were also used extensively to estimate the size of various market segments. The research methodology used to estimate the market size includes the following:
After determining the overall market size through the estimation process, the total market was divided into several segments and subsegments.
Genomics Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Genomics is a branch of molecular biology that involves the study of the structure, function, evolution, and mapping of genomes. It applies the techniques of genetics, molecular biology, and bioinformatics to sequence, assemble, and analyze the function and structure of the genome of a selected organism for analysis. Genomics is widely used in diagnostics, drug discovery and development, animal and agricultural research, forensics, and aquaculture research, among others.
Key Stakeholders
- Genomics Equipment and Consumable Manufacturing Companies
- Genomics Instrument/System Manufacturing Companies
- Suppliers and Distributors of Genomic Instruments/Systems, Consumables, and Services
- Hospitals, Diagnostic Centers, and Medical Colleges
- Research Institutes
- Hospitals and Academic Medical Centers (AMCs)
- Government Bodies/Municipal Corporations
- Business Research Firms
- Venture Capitalists
- Pharmaceutical and Biopharmaceutical Companies
Report Objectives
- To define, describe, and forecast the genomics market based on offering, product type, service type, product by technology, application, end user by product, end user by service, and region, in terms of value
- To forecast the size of the market segments with respect to six main regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa, in terms of value
- To provide detailed information regarding the major factors influencing market growth, such as drivers, restraints, opportunities, and challenges
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall genomics market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile key players in the genomics market and comprehensively analyze their product and service portfolios, market positions, and core competencies
- To track and analyze competitive developments in the genomics market, such as acquisitions, product & service launches, expansions, agreements, partnerships, and collaborations
- To benchmark players within the genomics market using the ‘Company Evaluation Matrix’ framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product & service portfolios of the top three companies.
Company Information
- Detailed analysis and profiling of additional market players (up to three).
Geographical Analysis
- A further breakdown of the Rest of Asia Pacific genomics market into countries
- A further breakdown of the Rest of Europe genomics market into countries
- A further breakdown of the Rest of Latin America genomics market into countries
- A further breakdown of the Rest of Middle East genomics market into countries
Get the Full Genomics Market Report
Full forecast, segment splits, and company analysis for all Genomics Market.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report